• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Sena Michael J. covered exercise/tax liability with 862 shares and was granted 12,946 shares, increasing direct ownership by 10% to 129,248 units (SEC Form 4)

    3/13/25 5:19:12 PM ET
    $VATE
    Metal Fabrications
    Industrials
    Get the next $VATE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Sena Michael J.

    (Last) (First) (Middle)
    295 MADISON AVENUE
    12TH FLOOR

    (Street)
    NEW YORK NY 10017

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    INNOVATE Corp. [ VATE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/11/2025 F(1) 862 D $7.23 116,302(2) D
    Common Stock 03/13/2025 A(3) 12,946 A $0 129,248 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares withheld by Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock.
    2. Effective August 8, 2024, the Issuer effected a ten-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.
    3. Reflects shares of restricted stock granted (the "Award") pursuant to the INNOVATE Corp. 2014 Omnibus Equity Award Plan, as amended from time to time (the "Plan"). Shares will vest and become exercisable in three installments of one-third each on the first, second and third anniversaries of the Date of Grant (each a "Vesting Date"), subject to the continued employment of the Reporting Person on the applicable Vesting Date.
    Remarks:
    /s/ Michael J. Sena 03/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VATE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VATE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VATE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INNOVATE Corp. Announces First Quarter 2025 Results

      - Infrastructure: DBM Global first quarter revenue of $264.9 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") System Received FDA Approval to Assess Kidney Function -- Spectrum: Expects commercial opportunities in datacasting to generate revenue by the end of the year - NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the first quarter. Financial Summary (in millions, except per share amounts)Three Months Ended March 31,  2025   2024  Increase / (Decrease)Revenue$274.2  $315.2  (13.0)%Net loss attributable to common stockholders and participating preferred stockholders$(24.8) $(

      5/6/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. to Report First Quarter 2025 Results on May 6th

      NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the first quarter 2025 on Tuesday, May 6, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the "Investor

      4/16/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results

      - Infrastructure: DBM Global fourth quarter revenue of $225.7 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") system received FDA approval to assess kidney function -- Spectrum: Broadcasting achieved double-digit revenue growth in the fourth quarter and full year 2024 - NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the fourth quarter. Financial Summary (in millions, except per share amounts)Three Months Ended December 31, Year Ended December 31,  2024   2023  Increase / (Decrease)  2024   2023  Increase / (Decrease)Revenue$236.6  $361.0  

      3/31/25 4:04:24 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    SEC Filings

    See more
    • SEC Form 10-Q filed by INNOVATE Corp.

      10-Q - INNOVATE Corp. (0001006837) (Filer)

      5/6/25 4:16:18 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INNOVATE Corp. (0001006837) (Filer)

      5/6/25 4:09:09 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • SEC Form DEFA14A filed by INNOVATE Corp.

      DEFA14A - INNOVATE Corp. (0001006837) (Filer)

      4/28/25 4:16:15 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Financials

    Live finance-specific insights

    See more
    • INNOVATE Corp. Announces First Quarter 2025 Results

      - Infrastructure: DBM Global first quarter revenue of $264.9 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") System Received FDA Approval to Assess Kidney Function -- Spectrum: Expects commercial opportunities in datacasting to generate revenue by the end of the year - NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the first quarter. Financial Summary (in millions, except per share amounts)Three Months Ended March 31,  2025   2024  Increase / (Decrease)Revenue$274.2  $315.2  (13.0)%Net loss attributable to common stockholders and participating preferred stockholders$(24.8) $(

      5/6/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. to Report First Quarter 2025 Results on May 6th

      NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the first quarter 2025 on Tuesday, May 6, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the "Investor

      4/16/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results

      - Infrastructure: DBM Global fourth quarter revenue of $225.7 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") system received FDA approval to assess kidney function -- Spectrum: Broadcasting achieved double-digit revenue growth in the fourth quarter and full year 2024 - NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the fourth quarter. Financial Summary (in millions, except per share amounts)Three Months Ended December 31, Year Ended December 31,  2024   2023  Increase / (Decrease)  2024   2023  Increase / (Decrease)Revenue$236.6  $361.0  

      3/31/25 4:04:24 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Sena Michael J. covered exercise/tax liability with 5,355 shares, decreasing direct ownership by 4% to 123,893 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      3/17/25 5:09:56 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Chief Financial Officer Sena Michael J. covered exercise/tax liability with 862 shares and was granted 12,946 shares, increasing direct ownership by 10% to 129,248 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      3/13/25 5:19:12 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Director Glazer Avram A received a gift of 4,195,804 shares and gifted 4,195,804 shares, decreasing direct ownership by 99% to 37,621 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      12/18/24 4:13:57 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by INNOVATE Corp.

      SC 13G/A - INNOVATE Corp. (0001006837) (Subject)

      11/13/24 9:30:32 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Amendment: SEC Form SC 13D/A filed by INNOVATE Corp.

      SC 13D/A - INNOVATE Corp. (0001006837) (Subject)

      6/21/24 7:05:53 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • SEC Form SC 13D/A filed by INNOVATE Corp. (Amendment)

      SC 13D/A - INNOVATE Corp. (0001006837) (Subject)

      4/1/24 4:18:15 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Interim CEO Voigt Paul bought $99,500 worth of shares (25,000 units at $3.98) (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      11/21/24 4:49:08 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Interim CEO Voigt Paul bought $166,383 worth of shares (43,785 units at $3.80), increasing direct ownership by 26% to 211,655 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      9/16/24 4:17:05 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Interim CEO Voigt Paul bought $106 worth of shares (176 units at $0.60), increasing direct ownership by 0.01% to 1,678,695 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      6/17/24 4:36:10 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Leadership Updates

    Live Leadership Updates

    See more
    • MediBeacon Inc. Appoints Dr. Steve Miller as Chief Medical Officer

      MediBeacon expands management team as enrollment in Phase 3 study focused on kidney disease is completed ST. LOUIS, May 16, 2023 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE:VATE), today announced the appointment of Dr. Steve Miller as chief medical officer. In this role, Dr. Miller will be focused on driving a range of clinical and strategic initiatives. Dr. Miller formerly served as executive vice president and chief clinical officer at Cigna, where he led the company's clinical policy, quality, and per

      5/16/23 7:00:00 AM ET
      $VATE
      Metal Fabrications
      Industrials
    • Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

      Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary. Mr. Ferraro will be responsible for managing Catalent's global legal and compliance operations. He will be based at the company's headquarters in Somerset, New Jersey, head up the company's Legal Leadership Team, and serve on its Executive Leadership Team, reporting directly to Catalent's Executive Vice President and Chief Administrative Officer, Steven Fasman. This press release features multimedia. View the full release here: https:/

      2/13/23 8:00:00 AM ET
      $CTLT
      $PSEC
      $VATE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • INNOVATE Corp. Announces Appointment of Amy Wilkinson to the Board of Directors

      NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE), today announced the appointment of Amy Wilkinson to fill the remaining vacancy on the INNOVATE Board of Directors. "Amy brings a unique blend of management expertise and global business and policy experience, and we are confident she will help guide us in our mission to drive shareholder value across our Infrastructure, Life Sciences and Spectrum operating segments," said Avie Glazer, Chairman of INNOVATE. "Amy's leadership and strategy consulting experience advising Fortune 500 companies will be a valuable addition to our Board," said Wayne Barr, Jr., Chief Executive Officer of INNOVATE

      8/2/22 4:15:00 PM ET
      $VATE
      Metal Fabrications
      Industrials